Novel approaches to antibody-drug-conjugate (ADC) analysis

Antibody-drug-conjugates (ADCs) are cancer biotherapeutics in which monoclonal antibodies specifically bind tumour cells and the conjugated cytotoxic payload is responsible for causing cancer cell death.

The combination of a small molecule to a protein poses additional challenges to their analysis.

This webinar will present (U)HPLC-based methods for ADC-characterisation: Drug-to-antibody-ratio (DAR) by an improved hydrophobic interaction chromatography (HIC) column, analysis of aggregated ADC and residual payload by size exclusion chromatography (SEC) and the use of a unique affinity-based method to characterise ADCs. 

For more information, please contact us at webinar@avantorsciences.com